New Clinical Guidelines Advise Nurse Practitioners on Expanding GLP-1 Receptor Agonist Indications and Risks

New clinical review explores GLP-1 benefits for heart and kidney health while warning of side effects and the dangers of unverified compounded medications.

By: AXL Media

Published: Apr 28, 2026, 5:54 AM EDT

Source: Information for this report was sourced from The Nurse Practitioner

The Expanding Horizon of Incretin Mimetic Therapy

The clinical landscape for glucagon-like peptide-1 receptor agonists (GLP-1RAs) is undergoing a rapid transformation, moving far beyond its original scope of type 2 diabetes management. A recent review in The Nurse Practitioner highlights that these agents, which mimic the endogenous GLP-1 hormone released after meals, are now being recognized for their systemic metabolic benefits. By enhancing glucose-dependent insulin secretion and suppressing glucagon, medications like semaglutide and tirzepatide are providing patients with unprecedented control over their metabolic health. Dr. Filippo Milano and other researchers note that as indications grow, the role of primary care providers in navigating these "multisystem therapies" has become increasingly complex.

Physiological Mechanisms and Multi-Receptor Target Success

At the cellular level, GLP-1RAs function by slowing gastric emptying and preserving pancreatic beta-cell function, which maintains prolonged metabolic activity due to their resistance to enzymatic degradation. The review notes that newer dual-agonist therapies, such as tirzepatide, add another layer of efficacy by targeting glucose-dependent insulinotropic polypeptide (GIP) receptors alongside GLP-1. This dual-action approach has resulted in significant clinical outcomes, with 30% to 80% of patients achieving hemoglobin A1c targets below 7%. These metabolic shifts are often accompanied by substantial weight reductions ranging from 5% to 20% over several months, fundamentally altering the treatment trajectory for patients with comorbid obesity.

Cardiovascular and Renal Protective Outcomes

Beyond the traditional metrics of blood sugar, GLP-1RAs are demonstrating profound cardioprotective and renoprotective qualities. Major medical guidelines now recommend these agents as first-line therapy for patients with type 2 diabetes who are at high risk for atherosclerotic cardiovascular disease or chronic kidney disease (CKD). Emerging data specifically point to semaglutide’s ability to reduce kidney-related risks and tirzepatide’s efficacy in treating moderate-to-severe obstructive sleep apnea in adults with obesity. These broad therapeutic effects suggest that the medications act as a comprehensive intervention for the metabolic syndrome cluster, rather than just a narrow glycemic tool.